Biosketch:

Ruben Deogracias obtained his PhD in Biochemistry, Molecular Biology and Biomedicine at the IIB-UAM in 2007. During his first Post-Doc at the Laboratory of Prof. Yves-Alain Barde at the Biozentrum of the University of Basel, Switzerland, he studied the molecular mechanisms involved in BDNF-dependent neuronal development and neurological disorders, specially focusing on MeCP2 and Rett Syndrome. In collaboration with Novartis he found that Fingolimod was able to cross the Blood Brain Barrier and induce an increment on BDNF that ameliorates Rett Syndrome progression, for what Novartis started the first worldwide clinical trials to tread Rett Syndrome. From this collaboration Dr. Deogracias is the inventor in 5 patents. In 2013 he started his second Post-Doc at the laboratory of Prof. Beatriz Rico were, first at the Instituto de Neurociencias de Alicante and later at the Centre for Developmental Neurobiology at the King´s College London, described the existence of different molecular mechanisms regulating synapse specification in cortical inhibitory circuits.

In 2017 Dr. Deogracias incorporated to ReNeuron LTD as Group Leader and Head of Discovery where he specialized in the use of neural stem cells and exosomes as new therapeutic agents for the treatment of cancer and neurological disorders. From this work Dr. Deogracias is the inventor of 2 patents.

In 2020 Dr. Deogracias, who obtained the second position as Ramon y Cajal Investigator at the area of Biomedicine, incorporated at the INCYL where he is actually leading the group of Neuronal Circuits Formation and brain disorders, where he and his team is focusing on the molecular mechanisms regulating the development of inhibitory GABAergic neuronal circuits in the mouse brain and their implications in pathological conditions.